Concepedia

Nagesh Gowda

NG

Statistics

Publications

5

Citations

210

H-Index

5

Active since

2013

Affiliations

Aurigene Discovery Technologies (India)(Current)

Nagesh Gowda is an author at Aurigene Discovery Technologies (India) specializing in pharmacology, immunotherapy, and cancer immunotherapy.

Publications per year

2013–2021

5

Publications

5

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi et al. · Communications Biology · 2021 · 149 citations · Full text

, , +17

Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats

Nagesh Gowda, Anilkumar Dandu, Jaideep Singh et al. · BMC Pharmacology and Toxicology · 2013 · 26 citations · Full text

, , +17

Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Nagaraj Gowda et al. · Cancer Research · 2016 · 13 citations

, , +17

Abstract B006: Functional antagonism of VSIG8-mediated immune suppression by oral VISTA agents

Pottayil G. Sasikumar, Sudarshan S. Naremaddepalli, Raghuveer Ramachandra et al. · Molecular Cancer Therapeutics · 2018 · 11 citations

, , +17

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Andreas Lundqvist, Vincent van Hoef, Xiaonan Zhang et al. · Journal for ImmunoTherapy of Cancer · 2016 · 11 citations · Full text

, , +13

1–5 of 5